Bioventus (BVS) Change in Accured Expenses (2020 - 2026)

Bioventus (BVS) has 7 years of Change in Accured Expenses data on file, last reported at -$15.4 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 60.7% year-over-year to -$15.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 128.17% YoY) and the FY2025 annual result came in at -$19.8 million, down 211.03% from the prior year.
• Change in Accured Expenses slipped to -$15.4 million in Q1 2026, from -$4.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $29.9 million in Q2 2024 to a low of -$39.1 million in Q1 2025.
• A 5-year average of -$1.5 million and a median of $2.3 million in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 911.94% — and 2024, when it surged 186.98%.
• Tracing BVS's Change in Accured Expenses over 5 years: stood at $14.3 million in 2022, then slumped by 59.53% to $5.8 million in 2023, then jumped by 186.98% to $16.6 million in 2024, then sank by 126.74% to -$4.4 million in 2025, then plunged by 245.79% to -$15.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$15.4 million (Q1 2026), -$4.4 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.